

Kolon Life Science Inc (102940) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/K59B2C41365EN.html>

Date: November 2021

Pages: 37

Price: US\$ 125.00 (Single User License)

ID: K59B2C41365EN

Abstracts

Kolon Life Science Inc (102940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kolon Life Science Inc (KLS) develops, manufactures, and commercializes active pharmaceutical ingredients, specialty chemicals and pharmaceutical products. Invossa, the company's lead product is the first cell-mediated gene therapy and is in Phase III for treating moderate (Kellgren and Lawrence grade 3) knee osteoarthritis in the US. The company's cell-mediated gene therapies are focused on providing medicine/drugs for treating degenerative diseases. Its pipeline product portfolio includes KLS-2031 for lumbosacral radiculopathy; and KLS-3021 for solid cancer among others. The company also offers water treatment solutions, anti-bacterial agents for paint and cosmetics. The company has manufacturing facilities in Chungju, Eumseong and in Gimcheon, all located in South Korea. KLS is headquartered in Gangseo-gu, Seoul, South Korea.

Kolon Life Science Inc Key Recent Developments

Jan 14,2021: Notice of the Arbitral Award on the license agreement with Kolon Life Science

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Kolon Life Science Inc - Key Facts
Kolon Life Science Inc - Key Employees
Kolon Life Science Inc - Key Employee Biographies
Kolon Life Science Inc - Major Products and Services
Kolon Life Science Inc - History
Kolon Life Science Inc - Company Statement
Kolon Life Science Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
Kolon Life Science Inc - Business Description
Business Segment: Biopharmaceuticals
Overview
Performance
Business Segment: Functional Materials
Overview
Performance
Business Segment: Medicine
Overview
Performance
Kolon Life Science Inc - SWOT Analysis
SWOT Analysis - Overview
Kolon Life Science Inc - Strengths
Kolon Life Science Inc - Weaknesses
Kolon Life Science Inc - Opportunities
Kolon Life Science Inc - Threats
Kolon Life Science Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart

Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Kolon Life Science Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jan 14, 2021: Notice of the Arbitral Award on the license agreement with Kolon Life Science

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Kolon Life Science Inc, Key Facts
Kolon Life Science Inc, Key Employees
Kolon Life Science Inc, Key Employee Biographies
Kolon Life Science Inc, Major Products and Services
Kolon Life Science Inc, History
Kolon Life Science Inc, Key Competitors
Kolon Life Science Inc, Ratios based on current share price
Kolon Life Science Inc, Annual Ratios
Kolon Life Science Inc, Annual Ratios (Cont...1)
Kolon Life Science Inc, Annual Ratios (Cont...2)
Kolon Life Science Inc, Interim Ratios
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kolon Life Science Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Kolon Life Science Inc, Performance Chart (2016 - 2020)

Kolon Life Science Inc, Ratio Charts

Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021

Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD
2021

I would like to order

Product name: Kolon Life Science Inc (102940) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/K59B2C41365EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K59B2C41365EN.html>